May 05, 2023 / 12:00PM GMT
Operator
Ladies and gentlemen, good day, and welcome to the Alembic Pharmaceuticals Limited Conference Call on discussion on company's Q4 and annual FY '23 Audited Financial Results. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. R.K. Baheti, Director of Finance and CFO. Thank you, and over to you, sir.
Raj Kumar Shreeram Baheti - Alembic Pharmaceuticals Limited - Director of Finance, CFO & Executive Director
Thank you. Good evening, everyone. Thank you all for joining the Fourth Quarter Annual Regional Conference Call. Let me start with the financials, and there are a few nondating or one-offs, which I'll try to explain. And then, of course, we'll take your questions.
So financials first. During the quarter, the total revenue is INR 1,406 crores, EBITDA is INR 205 crores, net property is INR 153 crores. EBITDA margin for the quarter is 14.5% -- for the full year FY '20, revenue is INR 5,643 crores, INR 653 crores, EBITDA is INR 680 crores and net profit is INR 342 crores.
Q4 2023 Alembic Pharmaceuticals Ltd Earnings Call Transcript
May 05, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers